Search Results - Türeci, Özlem

Özlem Türeci

Özlem Türeci in 2019 Özlem Türeci (; born 6 March 1967) is a German physician, scientist and entrepreneur. In 2008, she co-founded the biotechnology company BioNTech, which in 2020 developed the first messenger RNA-based vaccine approved for use against COVID-19. Türeci has served as BioNTech's chief medical officer since 2018. Since 2021, she has been Professor of Personalized Immunotherapy at the Helmholtz Institute for Translational Oncology (HI-TRON) and Johannes Gutenberg University Mainz. Türeci and her spouse, Uğur Şahin, have won a number of awards. Provided by Wikipedia
  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Cover Image

    A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics: comment by Meyer, Miriam (Author) , Mahr, Andrea (Author) , Brewer, Joanna (Author) , Daniel, Volker (Author) , Dell‘Aringa, Justine (Author) , Goldstone, Tony (Author) , Hersey, Sarah (Author) , Johnston, Ian (Author) , Larson, Pamela (Author) , Loveridge, Michael (Author) , MacBeath, Gavin (Author) , Moyer, Mark (Author) , Nagorsen, Dirk (Author) , Papa, Sophie (Author) , Peiser, Leanne (Author) , Ranade, Koustubh (Author) , Rizzi, Ruben (Author) , Roers, Axel (Author) , Schendel, Dolores (Author) , Sivakumar, Pallavur (Author) , Tran, Eric (Author) , Türeci, Özlem (Author) , Weigand, Luise (Author) , Wennborg, Anders (Author) , Williams, Dennis (Author) , Yee, Cassian (Author) , Britten, Cedrik Michael (Author) ,


    Get full text
    Article (Journal) Editorial Online Resource


    Saved in:
  2. 2
    Cover Image

    A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study by Türeci, Özlem (Author) , Sahin, Ugur (Author) , Schulze-Bergkamen, Henning (Author) ,


    Get full text
    Article (Journal) Online Resource


    Saved in:

Search Tools: